Merck & Co (MRK)
$125.89
0.04 (0.03%)
MRK Stock Quote Delayed 30 Minutes
3 Dow Stocks To Avoid
Buying yield can be a healthy strategy, but when it comes to three Dow stocks dogged-looking price charts may quickly trump income generation.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
318.67B
PE Ratio
139.88
EPS
0.9
Volume (Avg. Vol.)
689,665
Day's Range
$125.46 - $126.53
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.32%)
MRK Stock Predictions, Articles, and Merck & Co News
ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today
Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK).
7 Stocks to Buy to Give Your Portfolio a Booster Shot
With the omicron variant of Covid-19 already touching down in the U.S., here are the stocks to buy to inoculate your portfolio.
Orally Administered Covid-19 Treatment Should Bolster Merck’s Value
MRK stock can have a place in just about any safety-focused biopharmaceutical portfolio as the stock offers dividends at a good value.
Merck Is a Dividend Play Ready to Get Back in Gear
Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.
Once-Cinderella Novavax Stock Could Be Poisoned by Merck’s Covid Pill
With a new oral antiviral drug by Merck potentially over the horizon, NVAX stock may be trading on borrowed time.
Novavax News: Why NVAX Stock Investors Have a Tough Pill to Swallow Today
Novavax (NVAX) stock is taking a beating on Friday as investors react to news about Merck (MRK) developing a COVID-19 treatment.
Merck News: The ‘Game-Changer’ Making MRK Stock the No. 1 Trending Ticker Today
Merck (MRK) stock is taking off on Friday thanks to positive news from a clinical trial for treating COVID-19 with molnupiravir.
GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring
Today, a key announcement of some positive clinical trial data has sent investors in Galectin and GALT stock on a nice ride.
The Coronavirus Pill Makes Merck a Solid Buy
Merck is a great pharma play with its coronavirus pill and strong, consistent dividend payouts. MRK stock is a solid buy.
Motivation Really Matters When It Comes to Organon
Although spinoffs of well-known organizations have been known to outperform, you’ll want to examine OGN stock carefully.
Hold Merck for Its Solid Dividend and Covid-19 Treatment Prospects
MRK stock might not be an obvious "vaccine stock," but Merck's commitment to combating Covid-19 is commendable and potentially profitable.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Investors turned to new meme stocks like XERS and watched the OGN stock spinoff launch.
Merck Spinoff Organon Will Do Well Over Time
The Merck spinoff Organon will likely do quite well. OGN stock is likely to be worth $52.77, or 48% above the when-issued price right now.
